Detection of Fusions and TRK Expression and Performance of Pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Mar 25

PMID 35328221

Authors

Bart Koopman

Chantal C H J Kuijpers

Harry J M Groen

Wim Timens

Ed Schuuring

Stefan M Willems

Leon C van Kempen

Affiliations

Soon will be listed here.

Abstract

Gene fusions involving , and are rare drivers of cancer that can be targeted with histology-agnostic inhibitors. This study aimed to determine the nationwide landscape of /TRK testing in the Netherlands and the usage of pan-TRK immunohistochemistry (IHC) as a preselection tool to detect NTRK fusions. All pathology reports in 2017-2020 containing the search term 'TRK' were retrieved from the Dutch Pathology Registry (PALGA). Patient characteristics, tumor histology, /TRK testing methods, and reported results were extracted. /TRK testing was reported for 7457 tumors. Absolute testing rates increased from 815 (2017) to 3380 (2020). Tumors were tested with DNA/RNA-based molecular assay(s) (48%), IHC (47%), or in combination (5%). A total of 69 fusions involving ( = 22), ( = 6) and ( = 41) were identified in tumors from adult ( = 51) and pediatric ( = 18) patients. In patients tested with both IHC and a molecular assay ( = 327, of which 29 fusion-positive), pan-TRK IHC had a sensitivity of 77% (95% confidence interval (CI), 56-91) and a specificity of 84% (95% CI, 78-88%). These results showed that pan-TRK IHC has a low sensitivity in current routine practice and warrants the introduction of quality guidelines regarding the implementation and interpretation of pan-TRK IHC.

Citing Articles

Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.

Santi I, Vellekoop H, M Versteegh M, A Huygens S, Dinjens W, Rutten-van Molken M Mol Diagn Ther. 2024; 28(3):319-328.

PMID: 38616205 PMC: 11068666. DOI: 10.1007/s40291-024-00704-2.

Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland.

Zhang W, Schmitz A, Kallionpaa R, Perala M, Pitkanen N, Tukiainen M Oncotarget. 2024; 15:106-116.

PMID: 38329731 PMC: 10852057. DOI: 10.18632/oncotarget.28555.

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.

Vargas J, Pantouris G Int J Mol Sci. 2023; 24(21).

PMID: 37958963 PMC: 10650716. DOI: 10.3390/ijms242115981.

Kinase fusion positive intra-osseous spindle cell tumors: A series of eight cases with review of the literature.

Suurmeijer A, Xu B, Torrence D, Dickson B, Antonescu C Genes Chromosomes Cancer. 2023; 63(1):e23205.

PMID: 37782551 PMC: 11250992. DOI: 10.1002/gcc.23205.

Cost-Efficient Detection of Gene Fusions: Single-Center Analysis of 8075 Tumor Samples.

Romanko A, Mulkidjan R, Tiurin V, Saitova E, Preobrazhenskaya E, Krivosheyeva E Int J Mol Sci. 2023; 24(18).

PMID: 37762506 PMC: 10531831. DOI: 10.3390/ijms241814203.

References

Knezevich S, McFadden D, Tao W, Lim J, Sorensen P . A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998; 18(2):184-7. DOI: 10.1038/ng0298-184. View

Hechtman J, Benayed R, Hyman D, Drilon A, Zehir A, Frosina D . Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol. 2017; 41(11):1547-1551. PMC: 5636652. DOI: 10.1097/PAS.0000000000000911. View

Tognon C, Knezevich S, Huntsman D, Roskelley C, Melnyk N, Mathers J . Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002; 2(5):367-76. DOI: 10.1016/s1535-6108(02)00180-0. View

Solomon J, Linkov I, Rosado A, Mullaney K, Rosen E, Frosina D . NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2019; 33(1):38-46. PMC: 7437403. DOI: 10.1038/s41379-019-0324-7. View

Cocco E, Scaltriti M, Drilon A . NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15(12):731-747. PMC: 6419506. DOI: 10.1038/s41571-018-0113-0. View

Rudzinski E, Lockwood C, Stohr B, Vargas S, Sheridan R, Black J . Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol. 2018; 42(7):927-935. DOI: 10.1097/PAS.0000000000001062. View

van der Wekken A, Pelgrim R, t Hart N, Werner N, Mastik M, Hendriks L . Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2017; 23(15):4251-4258. DOI: 10.1158/1078-0432.CCR-16-1631. View

Carter-Febres M, Schneller N, Fair D, Solomon D, Perry A, Roy A . Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers. J Pediatr Hematol Oncol. 2020; 43(7):e987-e990. DOI: 10.1097/MPH.0000000000001983. View

Yeh I, Tee M, Botton T, Shain A, Sparatta A, Gagnon A . NTRK3 kinase fusions in Spitz tumours. J Pathol. 2016; 240(3):282-290. PMC: 5071153. DOI: 10.1002/path.4775. View

10.

Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I . Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014; 5:3116. PMC: 4084638. DOI: 10.1038/ncomms4116. View

11.

Pfarr N, Kirchner M, Lehmann U, Leichsenring J, Merkelbach-Bruse S, Glade J . Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays. Genes Chromosomes Cancer. 2019; 59(3):178-188. DOI: 10.1002/gcc.22819. View

12.

Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M, Ercan D . Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19(11):1469-1472. PMC: 3823836. DOI: 10.1038/nm.3352. View

13.

Farago A, Taylor M, Doebele R, Zhu V, Kummar S, Spira A . Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an Gene Fusion. JCO Precis Oncol. 2018; 2018. PMC: 6132056. DOI: 10.1200/PO.18.00037. View

14.

Gatalica Z, Xiu J, Swensen J, Vranic S . Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2018; 32(1):147-153. DOI: 10.1038/s41379-018-0118-3. View

15.

Penault-Llorca F, Rudzinski E, Sepulveda A . Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol. 2019; 72(7):460-467. PMC: 6589488. DOI: 10.1136/jclinpath-2018-205679. View

16.

Solomon J, Hechtman J . Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res. 2019; 79(13):3163-3168. PMC: 6606326. DOI: 10.1158/0008-5472.CAN-19-0372. View

17.

Sigal D, Bhangoo M, Hermel J, Pavlick D, Frampton G, Miller V . Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors. Oncotarget. 2018; 9(88):35809-35812. PMC: 6254675. DOI: 10.18632/oncotarget.26260. View

18.

Butter R, t Hart N, Hooijer G, Monkhorst K, Speel E, Theunissen P . Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. J Clin Pathol. 2019; 73(7):423-430. DOI: 10.1136/jclinpath-2019-205993. View

19.

Church A, Calicchio M, Nardi V, Skalova A, Pinto A, Dillon D . Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2017; 31(3):463-473. DOI: 10.1038/modpathol.2017.127. View

20.

Demetri G, Antonescu C, Bjerkehagen B, Bovee J, Boye K, Chacon M . Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020; 31(11):1506-1517. PMC: 7985805. DOI: 10.1016/j.annonc.2020.08.2232. View